Flamel Technologies S.A. (ADR) Stock price Nasdaq
Equities
US3384881096
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | 0.00% |
Financials (USD)
Sales 2024 * | 167M | Sales 2025 * | 301M | Capitalization | 1.53B |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | 91M | EV / Sales 2024 * | 9.53 x |
Net Debt 2024 * | 66.33M | Net cash position 2025 * | 5.71M | EV / Sales 2025 * | 5.05 x |
P/E ratio 2024 * |
-37.3
x | P/E ratio 2025 * |
21.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.35% |
Latest transcript on Flamel Technologies S.A. (ADR)
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
1st Jan change | Capi. | |
---|---|---|
+35.10% | 701B | |
+26.24% | 571B | |
+1.03% | 381B | |
+20.92% | 334B | |
+16.98% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-2.71% | 157B |
- Stock
- Equities
- Stock Avadel Pharmaceuticals plc
- Stock Flamel Technologies S.A. (ADR) - Nasdaq